The University of Oxford has launched the first human trial of a vaccine against Bundibugyo ebolavirus on July 13, 2026, racing to contain an outbreak that's now spreading beyond its original epicenter in the Democratic Republic of Congo and into Uganda. The early-stage trial, known as BD-Ebov, will evaluate the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged 18 to 55 in Oxford. Recruitment has begun, with vaccinations expected to start in the coming weeks pending regulatory approval.
The speed of this response underscores how serious the situation has become. The vaccine was developed by scientists at Oxford's Vaccine Group and Pandemic Sciences Institute using the same viral vector platform as the Oxford/AstraZeneca COVID-19 shot. Serum Institute of India, which is partnering on the programme, manufactured and stockpiled about 620,000 doses of the vaccine candidate within two weeks and supplied 4,000 investigational doses for the early-stage study. That's the kind of mobilization public health emergencies demand.
The Outbreak's Expanding Reach
The Ebola outbreak in the Democratic Republic of Congo has spread to two more northeastern provinces, Haut-Uele and Tshopo, according to the country's public health institute. The number of confirmed Ebola cases across the country rose to 1,926, including 702 deaths, as of late Sunday. Four cases were recorded in Tshopo, including two deaths, with one death confirmed in Haut-Uele, as of Saturday.
This expansion matters because it reveals how quickly the virus moves when detection and containment systems are strained. The latest Ebola outbreak, Congo's 17th, was declared on May 15 and had been largely concentrated in Ituri province, with cases also reported in North Kivu and South Kivu provinces. The often fatal viral disease spreads through direct contact with bodily fluids from infected people or animals and causes symptoms that can include high fever, vomiting and internal and external bleeding.
What's particularly troubling is that health authorities had started tracing people potentially exposed to Ebola in Tshopo and Haut-Uele in late June, but these two provinces hadn't been officially included in the government's daily reports until now. The National Institute of Public Health acknowledged this gap in its report dated July 11, stating: "Although current investigations suggest that all cases detected in these two provinces are primarily imported from Niania in Ituri, it is necessary and appropriate ... to consider these two provinces as an epidemic zone." Tshopo's provincial capital is Kisangani, one of Congo's largest cities. Haut-Uele shares borders with South Sudan and the Central African Republic, raising concerns about cross-border transmission.
The Real Numbers May Be Much Worse
Here's what should alarm public health officials everywhere: a senior World Health Organization official told Reuters last week that the true scale of the outbreak could be two to four times larger than official data indicate because four out of five new Ebola cases have no known link to existing patients. That gap between reported and actual cases suggests the virus is spreading faster and more widely than the numbers suggest, and that surveillance systems aren't catching it.
International Response and Access Questions
The World Health Organization recommended in May that ChAdOx1 BDBV vaccine, alongside a single-dose candidate known as rVSV Bundibugyo being developed by the International AIDS Vaccine Initiative, be prioritized for clinical evaluation as part of the response to the ongoing outbreak. The Coalition for Epidemic Preparedness Innovations said it would initially invest up to $8.6 million for the development of the shot. Preparations are also under way for additional clinical studies in Uganda, subject to regulatory approval, through partnerships including the Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene and Tropical Medicine Uganda Research Unit.
If the early-stage trial is successful, CEPI said it would work with Oxford and Serum Institute to support late-stage studies needed to seek emergency-use authorisation or full regulatory approval. The partners said they aim to ensure rapid and affordable vaccine supplies for affected countries. That commitment to affordability is crucial—vaccine access has historically been a problem in African nations during health crises, and this outbreak is happening in one of the world's poorest regions.
Why This Matters:
This outbreak reveals the fragility of disease surveillance systems in regions with limited resources and weak health infrastructure. When four out of five cases have no known epidemiological link, it means the virus is circulating in ways authorities can't track—a public health nightmare. The fact that provinces weren't officially counted as outbreak zones until weeks after cases appeared shows how gaps in reporting delay response. The vaccine development effort is commendable, but it comes after the outbreak has already killed 702 people and spread across multiple provinces. The real test will be whether vaccine access reaches affected populations quickly and equitably, and whether international support sustains beyond the initial clinical trials. Without investment in surveillance systems, healthcare worker training, and equitable vaccine distribution in Congo and neighboring countries, we'll face the same crisis again.